Nanobiotix (NASDAQ:NBTX) Sees Strong Trading Volume - Should You Buy?

Key Points

• Nanobiotix shares rose 3.3% to $45.05, with trading volume increasing 45% to approximately 119,459 shares.
• Analyst sentiment is mixed but leans positive: four analysts rate the stock a Buy, one rates it Hold and one Sell. The average rating is “Moderate Buy,” although the $37.33 average price target is below the current share price.
• Institutional investors own 38.81% of the company, while recent buyers included Millennium Management, Marshall Wace and Royal Bank of Canada. Nanobiotix is developing NBTXR3, a nanoparticle-based radioenhancer for cancer treatment, with CE Mark approval in Europe for soft tissue sarcoma.

Shares of Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX - Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 119,459 shares were traded during trading, an increase of 45% from the previous session's volume of 82,617 shares.The stock last traded at $45.05 and had previously closed at $44.50.

Wall Street Analysts Forecast Growth

NBTX has been the subject of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating on shares of Nanobiotix in a research report on Monday, May 18th. Leerink Partners increased their price objective on shares of Nanobiotix from $37.00 to $46.00 and gave the company an "outperform" rating in a research report on Thursday, June 4th. Weiss Ratings restated a "sell (d-)" rating on shares of Nanobiotix in a research note on Friday, July 17th. Finally, UBS Group lifted their target price on shares of Nanobiotix from $3.50 to $30.00 and gave the stock a "neutral" rating in a report on Friday, May 1st. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Nanobiotix presently has an average rating of "Moderate Buy" and an average price target of $37.33.

Nanobiotix Stock Up 3.3%

The stock has a fifty day simple moving average of $38.97 and a 200 day simple moving average of $35.90.

Institutional Investors Weigh In On Nanobiotix

Several large investors have recently bought and sold shares of the business. Millennium Management LLC bought a new position in Nanobiotix during the 4th quarter valued at about $390,000. Marshall Wace LLP bought a new stake in shares of Nanobiotix in the fourth quarter worth approximately $220,000. Finally, Royal Bank of Canada grew its stake in shares of Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company's stock worth $61,000 after acquiring an additional 2,500 shares during the period. 38.81% of the stock is currently owned by institutional investors.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company's lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.